TrialProstate cancer and prostatic diseases2025

A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

David R Wise et al.PubMed ↗Publisher ↗

No numbers read from the abstract.